{
  "data": {
    "id": "stat_MXHTJW2ETM154AEQRXSBFQJ79A",
    "url": "https://statorigin.org/stat/stat_MXHTJW2ETM154AEQRXSBFQJ79A",
    "indicator": {
      "slug": "ctgov-rnacv-trial-starts",
      "name": "Cardiometabolic RNA and next-generation lipid drug trial starts",
      "definition": "Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "US",
      "name": "United States",
      "type": "country"
    },
    "period": {
      "start": "2020-01-01",
      "end": "2020-12-31",
      "type": "year"
    },
    "value": 6,
    "value_text": "6 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States.",
      "quote": "{\"totalCount\":6,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_YTMP5F90D10N7AVQSBRPHTTK8H",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2020). ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran%20OR%20olpasiran%20OR%20lepodisiran%20OR%20zerlasiran%20OR%20pelacarsen%20OR%20muvalaplin%20OR%20zilebesiran%20OR%20plozasiran%20OR%20zodasiran%20OR%20solbinsiran%20OR%20olezarsen%20OR%20volanesorsen%20OR%20SLN360%20OR%20ARO-APOC3%20OR%20ARO-ANG3%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20lerodalcibep%20OR%20enlicitide%20OR%20MK-0616%20OR%20obicetrapib%20OR%20AZD0780%20OR%20vutrisiran%20OR%20patisiran%20OR%20eplontersen%20OR%20nucresiran%20OR%20TQJ230&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_MXHTJW2ETM154AEQRXSBFQJ79A",
      "bibtex": "@misc{clinicaltrialsgo2020ctgovfqj79a,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States},\n  year         = {2020},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_MXHTJW2ETM154AEQRXSBFQJ79A},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=inclisiran\\%20OR\\%20olpasiran\\%20OR\\%20lepodisiran\\%20OR\\%20zerlasiran\\%20OR\\%20pelacarsen\\%20OR\\%20muvalaplin\\%20OR\\%20zilebesiran\\%20OR\\%20plozasiran\\%20OR\\%20zodasiran\\%20OR\\%20solbinsiran\\%20OR\\%20olezarsen\\%20OR\\%20volanesorsen\\%20OR\\%20SLN360\\%20OR\\%20ARO-APOC3\\%20OR\\%20ARO-ANG3\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20lerodalcibep\\%20OR\\%20enlicitide\\%20OR\\%20MK-0616\\%20OR\\%20obicetrapib\\%20OR\\%20AZD0780\\%20OR\\%20vutrisiran\\%20OR\\%20patisiran\\%20OR\\%20eplontersen\\%20OR\\%20nucresiran\\%20OR\\%20TQJ230\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2020-01-01\\%2C2020-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}